 This is an open-label, randomized, parallel group pharmacokinetics trial of tipranavirritonavir TPVRTV, alone or in combination with RTV-boosted saquinavir SQV, amprenavir APV or lopinavir LPV, plus an optimized background regimen, in multiple antiretroviral ARV experienced HIV-1 patients. 